NEA Management Company as of June 30, 2026
Portfolio Holdings for NEA Management Company
NEA Management Company holds 26 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Trevi Therapeutics (TRVI) | 15.5 | $247M | 13M | 18.65 | |
| Mbx Biosciences (MBX) | 12.6 | $200M | 3.6M | 55.20 | |
| Monte Rosa Therapeutics (GLUE) | 11.7 | $186M | 7.7M | 24.20 | |
| Celcuity (CELC) | 11.3 | $179M | 1.7M | 104.62 | |
| Spyglass Pharma Com Shs (SGP) | 10.4 | $165M | 7.4M | 22.26 | |
| Savara (SVRA) | 9.5 | $151M | 25M | 6.16 | |
| Zenas Biopharma (ZBIO) | 6.4 | $102M | 4.0M | 25.38 | |
| Coursera (COUR) | 4.6 | $73M | 13M | 5.64 | |
| Aurinia Pharmaceuticals (AUPH) | 4.2 | $67M | 4.0M | 16.97 | |
| CRISPR Therapeutics Namen Akt (CRSP) | 3.6 | $58M | 1.1M | 54.54 | |
| Oric Pharmaceuticals (ORIC) | 2.8 | $45M | 4.1M | 10.83 | |
| Phathom Pharmaceuticals (PHAT) | 1.3 | $21M | 2.0M | 10.85 | |
| Korro Bio (KRRO) | 1.1 | $17M | 1.3M | 13.18 | |
| X4 Pharmaceuticals | 1.0 | $15M | 3.2M | 4.67 | |
| Champions Oncology Com New (CSBR) | 0.7 | $11M | 1.7M | 6.16 | |
| Nkarta (NKTX) | 0.6 | $10M | 3.6M | 2.83 | |
| CVRX (CVRX) | 0.6 | $10M | 2.0M | 5.14 | |
| Black Diamond Therapeutics (BDTX) | 0.5 | $8.2M | 4.4M | 1.85 | |
| Karyopharm Therapeutics Com New (KPTI) | 0.4 | $5.6M | 577k | 9.77 | |
| Inventiva SA Ads (IVA) | 0.3 | $5.5M | 1.5M | 3.78 | |
| Athira Pharma (LONA) | 0.3 | $4.3M | 464k | 9.19 | |
| Senti Biosciences Com New (SNTI) | 0.3 | $4.2M | 3.8M | 1.10 | |
| Marker Therapeutics Com New (MRKR) | 0.2 | $2.4M | 1.6M | 1.47 | |
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $2.2M | 479k | 4.56 | |
| Imagenebio (IMA) | 0.0 | $295k | 50k | 5.90 | |
| Gossamer Bio (GOSS) | 0.0 | $165k | 1.0M | 0.16 |
